title: [Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae].
abstract: BACKGROUND
  Infections produced by multidrug-resistant pathogens represent a therapeutic challenge because of the few therapeutic options available. Tigecycline is a relatively new antibiotic, with a wide spectrum of activity including some of these resistant bacteria. In adults is prescribed for the treatment of some infections caused by carbapenem resistant K. pneumoniae, however it has not been approved in children because of potential adverse effects in the dental enamel.
  
  
  METHODS
  Case series study. Medical records were reviewed in all children from 0 to 14 years of age that received tigecycline between January of 2008 and March of 2010.
  
  
  RESULTS
  9 patients received Tigecycline mainly for treatment of peritonitis, bacteremia, pneumonia and sepsis caused by carbapenem resistant K. pneumoniae. A dose of 1 mg/kg q 12 hours was administered to all patients. No adverse events were reported and a total of 6 patients had complete resolution of the infection.
  
  
  CONCLUSIONS
  Tigecycline could be considered a therapeutic option for treating infections produced by multidrug-resistant pathogens in children. The use in children is still compassionate and in this series of cases Tigecycline was well tolerated and safe.
authors.affiliation: Universidad Pontificia Bolivariana, Medellín, Colombia.
authors.forename: Isabel C
authors.initials: IC
authors.lastname: Hurtado
authors.forename: Mónica
authors.initials: M
authors.lastname: Trujillo
authors.forename: Andrea
authors.initials: A
authors.lastname: Restrepo
authors.forename: Carlos
authors.initials: C
authors.lastname: Garcés
authors.forename: Carolina
authors.initials: C
authors.lastname: Tamayo
authors.forename: Juan G
authors.initials: JG
authors.lastname: Mesa
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015780:Carbapenems / Q000627:therapeutic use*; D002675:Child, Preschool; D057176:Compassionate Use Trials / Q000379:methods*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007223:Infant; D007710:Klebsiella Infections / Q000188:drug therapy* / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects*; D008297:Male; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D000078304:Tigecycline; D018440:beta-Lactam Resistance / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000078304:Tigecycline; D008911:Minocycline